Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024
Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024
TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results after the close of the U.S. markets on Tuesday July 30, 2024. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET.
2024年7月23日,佛罗里达州坦帕 – Pacira BioSciences,Inc. (纳斯达克:PCRX) 宣布将于2024年7月30日(星期二)美国股市收盘后公布2024年第二季度财报。公司在财报公布后将于美国东部时间下午4点30分举行电话会议和网络研讨会。
For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the "Events" page on the Pacira website at investor.pacira.com. For those unable to participate in the live call, a replay of the webcast will be available on the Pacira website for approximately two weeks following the call.
如想通过电话参加问题与回答环节,请在此预先注册。所有注册人将收到拨入信息和PIN码,以便他们参加现场呼叫。此外,电话会议的实况音频也将作为网络研讨会提供。对此感兴趣的人可以在Pacira投资者网站的“事件”页面上访问此活动。对于无法参加现场呼叫的人,电话会议的网络研讨会重播将在呼叫后约两周内在Pacira网站上提供。
About Pacira
关于Pacira
Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. The company is also developing innovative interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain, and spasticity. Pacira has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting, local analgesia currently approved for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain; and ioverao, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit .
Pacira Biosciences, Inc.(Nasdaq:PCRX)致力于为尽可能多的患者提供无阿片类选择,将阿片类药物重新定义为仅供抢救治疗。该公司还正在开发创新的干预措施,以解决涉及交感神经系统的令人沮丧的病症,例如心脏电风暴、慢性疼痛和痉挛性。Pacira拥有三个商业化阶段的非阿片类治疗方法:EXPAREL (bupivacaine liposome injectable suspension),一种长效局部麻醉,目前获得了术后疼痛管理的批准;ZILRETTA (triamcinolone acetonide extended-release injectable suspension),一种延长释放的关节内注射,适用于治疗骨关节炎膝关节疼痛;iovera,一种新型手持装置,可使用精确控制剂量的低温在定向神经上提供即时、长效且无药物控制疼痛。要了解有关Pacira的更多信息,包括降低过度依赖阿片类药物的公司使命,请访问。
Investor Contact:Pacira BioSciences, Inc.Christian Pedetti, (973) 254-4387Christian.Pedetti@pacira.com
投资者联系人:Pacira生物科学公司,克里斯蒂安·佩德蒂,(973) 254-4387,Christian.Pedetti@pacira.com